In line with this, in breast cancer, Notch1 and miR-34 expressions were inversely correlated, and miR-34 mimic sensitized chemoresistant breast cancer cells to doxorubicin and paclitaxel, thus suggesting a possible advantage of Notch inhibition by replacing miR-34 in combined therapeutic strategies [307,309,310]. This evidence concerns the gene NOTCH1 and breast carcinoma.